Volume 13, Issue 1 (Feb 2025)
Res Mol Med (RMM) 2025, 13(1): 1-8 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimbakhsh M, Eramian M, Gholami M. Staphylococcus haemolyticus: Tackling Multidrug Resistance and Biofilm Hurdles–Advances in Antimicrobial Strategies: A Review Study. Res Mol Med (RMM) 2025; 13 (1) :1-8
URL: http://rmm.mazums.ac.ir/article-1-598-en.html
URL: http://rmm.mazums.ac.ir/article-1-598-en.html
1- Department of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Molecular and Cell Biology Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. ,mehrdad_gholami90@yahoo.com
2- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Molecular and Cell Biology Research Centre, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. ,
Abstract: (1122 Views)
Background: Staphylococcus haemolyticus, an emerging coagulase-negative staphylococcus (CoNS), drives hospital-acquired infections (HAIs) in immunocompromised patients and those with indwelling devices, fueled by its multidrug resistance (MDR) and robust biofilm formation. Despite its clinical significance, S. haemolyticus remains understudied compared to other staphylococci.
Materials and Methods: A systematic literature review was conducted using PubMed and Google Scholar from 2020 to 2025. Keywords included S. haemolyticus AND (MDR OR biofilm OR phage therapy OR ‘antimicrobial peptides [AMPs]). The inclusion criteria comprised peer-reviewed articles on mechanisms, epidemiology, or therapies in humans and animals. The initial search yielded 1,247 hits; after the removal of duplicates (n=312) and title/abstract screening, 156 full texts were assessed.
Results: S. haemolyticus exhibits MDR primarily through mecA-mediated methicillin resistance and horizontal gene transfer (HGT). Biofilm formation enhances antibiotic tolerance and immune evasion. Key virulence factors, including surface proteins and phenol-soluble modulins, contribute significantly to its pathogenesis. Novel therapeutic approaches, such as antimicrobial peptides and bacteriophage therapy, demonstrate promising efficacy against MDR strains in preclinical studies.
Conclusion: This review highlights S. haemolyticus as an underestimated threat in HAIs, emphasizing the need for targeted therapies and advanced diagnostics. Future research should focus on clinical trials for novel antimicrobials, global epidemiology, and omics-driven drug discovery to combat this resilient pathogen.
Materials and Methods: A systematic literature review was conducted using PubMed and Google Scholar from 2020 to 2025. Keywords included S. haemolyticus AND (MDR OR biofilm OR phage therapy OR ‘antimicrobial peptides [AMPs]). The inclusion criteria comprised peer-reviewed articles on mechanisms, epidemiology, or therapies in humans and animals. The initial search yielded 1,247 hits; after the removal of duplicates (n=312) and title/abstract screening, 156 full texts were assessed.
Results: S. haemolyticus exhibits MDR primarily through mecA-mediated methicillin resistance and horizontal gene transfer (HGT). Biofilm formation enhances antibiotic tolerance and immune evasion. Key virulence factors, including surface proteins and phenol-soluble modulins, contribute significantly to its pathogenesis. Novel therapeutic approaches, such as antimicrobial peptides and bacteriophage therapy, demonstrate promising efficacy against MDR strains in preclinical studies.
Conclusion: This review highlights S. haemolyticus as an underestimated threat in HAIs, emphasizing the need for targeted therapies and advanced diagnostics. Future research should focus on clinical trials for novel antimicrobials, global epidemiology, and omics-driven drug discovery to combat this resilient pathogen.
Keywords: Staphylococcus haemolyticus, Multidrug resistance (MDR), Biofilm, Antimicrobial peptides, Phage therapy
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
